Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VR-CAP in First-line Treatment for Marginal Zone Lymphoma
NCT04433156Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2020
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in marginal zone lymphoma (MZL), sponsored by Henan Cancer Hospital. Started Apr 2020; status: completed.
02
Drugs
bortezomib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04433156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433156.